StockNews.AI
VXRT
StockNews.AI
21 days

Vaxart Announces Adjournment of Special Meeting of Stockholders

1. Vaxart's special stockholder meeting adjourned to September 19, 2025. 2. Stockholders encouraged to vote on proposals by September 18, 2025. 3. Changes in Board and governance may affect upcoming proposals. 4. Importance of Nasdaq listing highlighted for stockholder value. 5. Reverse stock split proposal pending further stockholder consideration.

9m saved
Insight
Article

FAQ

Why Bullish?

The adjournment allows stockholders to better assess the importance of the proposals, potentially leading to higher approval rates. Historically, companies seeing increased engagement with stockholders often experience positive price movements.

How important is it?

The outcome of the stockholder proposals directly affects VXRT's financial stability and market perception, thus influencing its stock price. Increased focus on governance can often bolster investor confidence.

Why Short Term?

The upcoming vote on September 19 suggests immediate ramifications for stock price based on stockholder decisions. Recent examples show short-term price spikes following positive shareholder meetings and votes.

Related Companies

NVAXBNTXMRNA
September 08, 2025 08:00 ET  | Source: Vaxart, Inc. Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 special meeting of stockholders (the “Special Meeting”) has been adjourned to Friday, September 19, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 6, 2025 (the “Proxy Statement”). “We continue to believe that a listing on Nasdaq is integral to advancing our science and maximizing stockholder value,” said Steven Lo, Chief Executive Officer of Vaxart. “We look forward to engaging with our stockholders over the next two weeks to discuss this important issue and listen to their feedback.” The reverse stock split proposal was not voted on at the September 5th Special Meeting because the Board of Directors would like to provide stockholders with additional time to consider and vote in light of recent changes in Board composition, additional governance changes that the Board is considering and may announce, as well as potential other disclosures from the Company. The reconvened Special Meeting will be held in a virtual-only format, which can be accessed by visiting http://www.virtualshareholdermeeting.com/VXRT2025 and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials. During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement. Proxies previously submitted with respect to the Special Meeting will be voted on all applicable proposals at the adjourned Special Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on September 18, 2025. The Company also reminds those who have previously voted against reverse stock split proposal that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart’s proxy solicitation firm: Campaign Management, LLCToll-Free: 1-855-264-1527Email: info@campaign-mgmt.com About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections, concerning our business, operations, and financial performance and condition as well as the special meeting of stockholders, our plans, objectives, and expectations for business operations, funding, any ability to stay listed on Nasdaq, any ability to regain and maintain compliance with the Bid Price Rule, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as “anticipate,” “assume,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under “Item 1A - Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the SolicitationThe Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the special meeting of stockholders to be held on September 19, 2025. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the special meeting of stockholders as well as the Company’s other filings with the U.S. Securities and Exchange Commission (the “SEC”), all of which may be obtained free of charge at the website maintained by the SEC at www.sec.gov. Contact Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@vaxart.com(646) 871-8481 This press release was published by a CLEAR® Verified individual.

Related News